Promising Developments and Strategic Timing Boost Crispr Therapeutics AG’s Prospects: A Buy Recommendation by Mitchell Kapoor

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $65.00.

Mitchell Kapoor has given his Buy rating due to a combination of factors related to Crispr Therapeutics AG’s promising developments and strategic decisions. The updated data from the Phase 1 trial of CTX310, an in vivo gene editing therapy targeting ANGPTL3, has shown significant reductions in triglycerides and LDL cholesterol at higher doses, with a favorable safety profile. This positions CTX310 as a potentially transformative therapy, offering a one-time treatment option that could lead to permanent benefits and improved patient compliance.
Additionally, the strategic delay in the release of CTX320 data is seen as a calculated move to align with the anticipated Phase 3 results from Novartis and Ionis. This timing aims to provide a robust context for CTX320’s significance in targeting Lp(a), enhancing the potential impact of its results. Kapoor’s positive outlook is further supported by the potential readthroughs from competitors’ data, which could provide tailwinds for Crispr Therapeutics AG’s stock.